A higher number of HER2-positive CTCs (≥3) was found in 25.8% of HER2-positive BC, while in HER2-negative patients only one (2.5%) was found to have ≥3 HER2-positive CTCs. This evidence concerns the gene ERBB2 and breast cancer.